Publications by authors named "D J Mahler"

Photonics offers a promising platform for quantum computing, owing to the availability of chip integration for mass-manufacturable modules, fibre optics for networking and room-temperature operation of most components. However, experimental demonstrations are needed of complete integrated systems comprising all basic functionalities for universal and fault-tolerant operation. Here we construct a (sub-performant) scale model of a quantum computer using 35 photonic chips to demonstrate its functionality and feasibility.

View Article and Find Full Text PDF

Rensch's Rule describes a pattern of interspecific allometry in which sexual size dimorphism (SSD) increases with size among closely related species (i.e., among a group of related species, the largest ones tend to show more male-biased SSD).

View Article and Find Full Text PDF

Purpose: Several lung function endpoints are utilized in clinical trials of inhaled bronchodilators for chronic obstructive pulmonary disease (COPD). Trough forced expiratory volume in 1 second (FEV) is a commonly reported endpoint in COPD trials and can be complemented by area under the FEV vs time curve (FEV AUC), which provides information on duration and consistency of bronchodilation over a dosing interval. Revefenacin, a once-daily bronchodilator, significantly improved lung function in patients with COPD when measured by trough FEV in two replicate Phase 3 trials.

View Article and Find Full Text PDF

Many hypotheses in the field of phylogenetic comparative biology involve specific changes in the rate or process of trait evolution. This is particularly true of approaches designed to connect macroevolutionary pattern to microevolutionary process. We present a method to test whether the rate of evolution of a discrete character has changed in one or more clades, lineages, or time periods.

View Article and Find Full Text PDF
Article Synopsis
  • Dyspnea is a key concern in chronic obstructive pulmonary disease (COPD), and the study evaluated the effects of a drug called ensifentrine on this issue using data from Phase 3 trials.
  • In the trials, ensifentrine was tested on 975 patients with COPD, showing significant improvements in dyspnea scores and reduced use of rescue medication after 24 weeks compared to 574 patients on a placebo.
  • The study concluded that ensifentrine effectively alleviated dyspnea for moderate-to-severe COPD patients, although it did not include those already on certain combination therapies.
View Article and Find Full Text PDF